KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Exchange Rate Effect (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Exchange Rate Effect for 17 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Exchange Rate Effect rose 107.23% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $71.0 million through Dec 2025, up 173.96% year-over-year, with the annual reading at $71.0 million for FY2025, 173.96% up from the prior year.
  • Exchange Rate Effect hit $6.0 million in Q4 2025 for Abbott Laboratories, up from -$10.0 million in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $51.0 million in Q4 2022 to a low of -$96.0 million in Q3 2022.
  • Historically, Exchange Rate Effect has averaged -$12.0 million across 5 years, with a median of -$11.5 million in 2021.
  • Biggest YoY gain for Exchange Rate Effect was 492.31% in 2022; the steepest drop was 1875.0% in 2022.
  • Year by year, Exchange Rate Effect stood at -$13.0 million in 2021, then skyrocketed by 492.31% to $51.0 million in 2022, then tumbled by 50.98% to $25.0 million in 2023, then crashed by 432.0% to -$83.0 million in 2024, then surged by 107.23% to $6.0 million in 2025.
  • Business Quant data shows Exchange Rate Effect for ABT at $6.0 million in Q4 2025, -$10.0 million in Q3 2025, and $51.0 million in Q2 2025.